ClinicalTrials.gg

Program

baloxavir

Also written as “Baloxavir Marboxil” and “Baloxavir marboxil”.

Its studies are mostly in Influenza, Human, led by 2 companies.

Furthest: phase 3, since Aug 10, 201810 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche82 open or runningphase 3since Aug 10, 2018Aug 10, 2018Apr 30, 2027phase 3 · NCT07827599
Shionogi20 open or runningphase 3since Oct 27, 2016Oct 27, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2016First studies: 2 phase 3 studies in Influenza, HumanNew to ShionogiShionogi · NCT02954354, NCT02949011
  2. Aug 10, 2018Hoffmann-La Roche's first studies: 2 phase 3 studies in Influenza, HumanNew to Hoffmann-La RocheHoffmann-La Roche · NCT03629184, NCT03653364
  3. Sep 24, 2018Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT03684044 · 363 enrolled · United States, Argentina, Australia and more
  4. May 21, 2019No phase study in Healthy VolunteerHoffmann-La Roche · NCT03959332 · 32 enrolled · China
  5. May 29, 2019Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT03969212 · 4,138 enrolled · United States, Bulgaria, China and more
  6. Oct 17, 2023Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06094010 · 1,100 planned · United States, Bulgaria, Poland and more
  7. Jan 9, 2025Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06774859 · 100 enrolled · China
  8. Sep 15, 2026Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT07827599 · 325 planned · China

Ahead

  1. Apr 30, 2027Primary completion: phase 3 study in Influenza, HumanHoffmann-La Roche · NCT07827599
  2. May 11, 2027Primary completion: phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06094010

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Polymerase acidic protein inhibitor; Polymerase acidic protein inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07827599Influenza, Human · China3RecruitingHoffmann-La RocheApr 30, 2027325
NCT06774859Influenza, Human · China3CompletedHoffmann-La RocheMay 8, 2025100
NCT06094010Influenza, Human · United States, Bulgaria, Poland and more3RecruitingHoffmann-La RocheMay 11, 20271,100
NCT03969212Influenza, Human · United States, Bulgaria, China and more3CompletedHoffmann-La RocheMay 10, 20244,138
NCT03959332Healthy Volunteer · China–CompletedHoffmann-La RocheJul 11, 201932
NCT03684044Influenza, Human · United States, Argentina, Australia and more3CompletedHoffmann-La RocheMar 16, 2020363
NCT03653364Influenza, Human · United States, Bulgaria, Costa Rica and more3CompletedHoffmann-La RocheApr 3, 202349
NCT03629184Influenza, Human · United States, Costa Rica, Israel and more3CompletedHoffmann-La RocheApr 3, 2019173
NCT02954354Influenza, Human3CompletedShionogiApr 4, 20171,436
NCT02949011Influenza, Human3CompletedShionogiApr 12, 20182,184

How it is read

Names in the registry

  • “Baloxavir Marboxil”, 9 entries
  • “Baloxavir marboxil”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.